{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:51:09Z","timestamp":1781891469808,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.retram.2026.103586","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:02:29Z","timestamp":1775145749000},"page":"103586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of the rest period between sequential chemotherapy and conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for high-risk myeloid malignancies"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4866-8520","authenticated-orcid":false,"given":"Valentin","family":"Amenta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sonet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Collinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Dachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Baiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Bihin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Poir\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Graux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2026.103586_bib0001","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103586_bib0002","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41409-025-02701-3","article-title":"Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations","volume":"60","author":"Greco","year":"2025","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.retram.2026.103586_bib0003","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential Regimen of Chemotherapy, Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation, and Prophylactic Donor Lymphocyte Transfusion in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.retram.2026.103586_bib0004","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s00277-020-04131-1","article-title":"The FLAMSA concept-past and future","volume":"99","author":"Kolb","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.retram.2026.103586_bib0005","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3324\/haematol.2018.203869","article-title":"Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience","volume":"104","author":"Ram","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.retram.2026.103586_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8091437","article-title":"FLAMSA-RIC for Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis","volume":"8","author":"Owattanapanich","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.retram.2026.103586_bib0007","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41409-022-01611-y","article-title":"Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed\/refractory acute myeloid leukemia: an EBMT analysis","volume":"57","author":"Rodriguez-Arboli","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.retram.2026.103586_bib0008","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.bbmt.2020.07.020","volume":"26","author":"Rodr\u00edguez-Arbol\u00ed","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.retram.2026.103586_bib0009","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.retram.2026.103586_bib0010","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","article-title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial","volume":"11","author":"Stelljes","year":"2024","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.retram.2026.103586_bib0011","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103586_bib0012","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjh.15137","article-title":"High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia","volume":"180","author":"Steckel","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.retram.2026.103586_bib0013","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbmt.2018.01.005","article-title":"Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors","volume":"24","author":"Dulery","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.retram.2026.103586_bib0014","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3324\/haematol.2016.150326","article-title":"Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia","volume":"102","author":"Mohty","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.retram.2026.103586_bib0015","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3390\/cancers16030532","article-title":"Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies","volume":"16","author":"Schulz","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.retram.2026.103586_bib0017","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.retram.2026.103586_bib0018","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.retram.2026.103586_bib0019","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1016\/S2352-3026(18)30156-X","article-title":"Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial","volume":"5","author":"Popat","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.retram.2026.103586_bib0020","first-page":"307","article-title":"Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial","volume":"9","author":"Karp","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.retram.2026.103586_bib0021","first-page":"3600","article-title":"Enhancement of drug cytotoxicity by recruitment of leukemic myeloblasts with humoral stimulation","volume":"36","author":"Karp","year":"1976","journal-title":"Cancer Res"},{"key":"10.1016\/j.retram.2026.103586_bib0022","first-page":"2138","article-title":"Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors","volume":"37","author":"Burke","year":"1977","journal-title":"Cancer Res"},{"key":"10.1016\/j.retram.2026.103586_bib0023","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2003-10-3561","article-title":"Randomized comparison of double induction and timed-sequential induction to a \"3 + 7\" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study","volume":"104","author":"Castaigne","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103586_bib0024","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.leukres.2009.11.007","article-title":"Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia","volume":"34","author":"Karp","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.retram.2026.103586_bib0025","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00277-013-1774-5","article-title":"Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia","volume":"92","author":"Schneidawind","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.retram.2026.103586_bib0026","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1016\/j.bbmt.2011.12.345","article-title":"Outcome of High-Risk and Refractory AML\/MDS Patients Receiving a Flamsa Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)","volume":"18","author":"Detrait","year":"2012","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.retram.2026.103586_bib0027","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.bbmt.2011.09.006","article-title":"Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen","volume":"18","author":"Saure","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.retram.2026.103586_bib0028","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00277-011-1253-9","article-title":"Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia","volume":"91","author":"Chemnitz","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.retram.2026.103586_bib0029","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1600-0609.2011.01703.x","article-title":"Cytoreductive treatment with clofarabine\/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome","volume":"88","author":"Buchholz","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.retram.2026.103586_bib0030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-019-0727-4","volume":"12","author":"Saraceni","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.retram.2026.103586_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106300","article-title":"Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'","volume":"90","author":"Scheckel","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.retram.2026.103586_bib0032","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bjh.14428","article-title":"Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT","volume":"176","author":"Ringden","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.retram.2026.103586_bib0033","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.2023022273","article-title":"Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?","volume":"144","author":"Scheid","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103586_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.08.007","article-title":"Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes","volume":"27","author":"Oran","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.retram.2026.103586_bib0035","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ajh.27172","article-title":"Comparison of fludarabine-based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry-based study","volume":"99","author":"Kurita","year":"2024","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.retram.2026.103586_bib0036","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/bloodadvances.2019001266","article-title":"Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report","volume":"4","author":"Zhou","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.retram.2026.103586_bib0037","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3324\/haematol.2022.280798","article-title":"New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia","volume":"108","author":"Mohty","year":"2023","journal-title":"Haematologica"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245231862600022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245231862600022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:56:30Z","timestamp":1781888190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S245231862600022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S245231862600022X"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2026.103586","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the rest period between sequential chemotherapy and conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for high-risk myeloid malignancies","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2026.103586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103586"}}